Regeneron Enterprise Value Over E B I T D A from 2010 to 2024

REGN Stock  USD 893.99  7.20  0.80%   
Regeneron Pharmaceuticals Enterprise Value Over EBITDA yearly trend continues to be very stable with very little volatility. Enterprise Value Over EBITDA is likely to grow to 26.26 this year. During the period from 2010 to 2024, Regeneron Pharmaceuticals Enterprise Value Over EBITDA quarterly data regression pattern had sample variance of  1,407 and median of  18.26. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
18.26210854
Current Value
26.26
Quarterly Volatility
37.51408846
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Regeneron Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regeneron main balance sheet or income statement drivers, such as Depreciation And Amortization of 442.1 M, Interest Expense of 76.7 M or Total Revenue of 13.8 B, as well as many exotic indicators such as Price To Sales Ratio of 6.79, Dividend Yield of 0.007 or PTB Ratio of 5.22. Regeneron financial statements analysis is a perfect complement when working with Regeneron Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Regeneron Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Regeneron Pharmaceuticals Technical models . Check out the analysis of Regeneron Pharmaceuticals Correlation against competitors.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Latest Regeneron Pharmaceuticals' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Regeneron Pharmaceuticals over the last few years. It is Regeneron Pharmaceuticals' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regeneron Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Pretty Stable
   Enterprise Value Over E B I T D A   
       Timeline  

Regeneron Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean15.31
Geometric Mean25.89
Coefficient Of Variation244.97
Mean Deviation22.16
Median18.26
Standard Deviation37.51
Sample Variance1,407
Range156
R-Value0.29
Mean Square Error1,391
R-Squared0.08
Significance0.30
Slope2.41
Total Sum of Squares19,702

Regeneron Enterprise Value Over E B I T D A History

2024 26.26
2023 18.26
2022 14.86
2021 7.09
2020 13.57
2019 18.15
2018 16.62

About Regeneron Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Regeneron Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Regeneron Pharmaceuticals investors use historical funamental indicators, such as Regeneron Pharmaceuticals's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Regeneron Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Regeneron Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Regeneron Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Regeneron Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Regeneron Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 18.26  26.26 

Currently Active Assets on Macroaxis

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out the analysis of Regeneron Pharmaceuticals Correlation against competitors.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.03)
Earnings Share
34.78
Revenue Per Share
122.935
Quarterly Revenue Growth
0.006
Return On Assets
0.0849
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.